About this episode

Dr. Mary-Ellen Taplin discusses the latest changes to the living guideline on metastatic castration-resistant prostate cancer.

Dr. Mary-Ellen Taplin joins the podcast to discuss the latest changes to the living guideline on metastatic castration-resistant prostate cancer (mCRPC). She reviews new treatment options for patients treated with ADT alone, ADT and an ARPI, ADT and docetaxel, and ADT, an ARPI, and docetaxel whose disease has progressed to mCRPC and the evidence that underpins these changes. Dr. Taplin highlights the updated algorithms within the guideline and the living format which will provide rapid, up-to-date, evidence-based information for clinicians and patients. Read the full living guideline update, "Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1." at www.asco.org/genitourinary-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/genitourinary-cancer-guidelines . Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-02693 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information…

People in this episode

Host: Brittany Harvey

Guest: Dr. Mary-Ellen Taplin

Topics covered

• metastatic castration-resistant prostate cancer
• ASCO guidelines
• systemic therapy
• treatment options
• evidence-based medicine

Keywords

• mCRPC
• ADT
• ARPI
• docetaxel
• treatment options
• clinical guidelines
• oncology

Mentioned in this episode

Organizations: American Society of Clinical Oncology, Dana-Farber Cancer Institute, Journal of Clinical Oncology

Books & works: Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1

More episodes of ASCO Guidelines

• Systemic Treatment of Thyroid Cancer Guideline · April 1, 2026 · 23 min
• Patient-Clinician Communication Guideline Update · March 10, 2026 · 31 min
• Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer Guideline Update · February 26, 2026 · 29 min
• White Blood Cell Growth Factors Guideline Update · February 25, 2026 · 23 min
• Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 2 · February 3, 2026 · 20 min
• Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 1 · February 3, 2026 · 18 min

Explore listener stats, chart rankings, contacts and more on the ASCO Guidelines podcast page.